Windtree Therapeutics Inc (WINT) - Total Assets
Based on the latest financial reports, Windtree Therapeutics Inc (WINT) holds total assets worth $15.98 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See WINT net assets for net asset value and shareholders' equity analysis.
Windtree Therapeutics Inc - Total Assets Trend (1995–2024)
This chart illustrates how Windtree Therapeutics Inc's total assets have evolved over time, based on quarterly financial data.
Windtree Therapeutics Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Windtree Therapeutics Inc's total assets of $15.98 Million consist of 9.2% current assets and 90.8% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 6.4% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $24.13 Million | 86.6% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (1995–2024)
This chart illustrates how Windtree Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Windtree Therapeutics Inc (WINT) market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Windtree Therapeutics Inc's current assets represent 9.2% of total assets in 2024, a decrease from 100.0% in 1995.
- Cash Position: Cash and equivalents constituted 6.4% of total assets in 2024, up from 0.0% in 1995.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 86.0% of total assets, an increase from 0.0% in 1995.
- Asset Diversification: The largest asset category is intangible assets at 86.6% of total assets.
Windtree Therapeutics Inc Competitors by Total Assets
Key competitors of Windtree Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Argen-X
F:1AE
|
Germany | €7.18 Billion |
|
Metsera, Inc. Common Stock
NASDAQ:MTSR
|
USA | $639.66 Million |
|
Zhejiang Ausun Pharmaceutical Co Ltd
SHG:603229
|
China | CN¥3.06 Billion |
|
R&G PharmaStudies Co. Ltd. A
SHE:301333
|
China | CN¥2.31 Billion |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197
|
China | CN¥819.45 Million |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253
|
China | CN¥2.16 Billion |
Windtree Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.33 | 0.27 | 2.96 |
| Quick Ratio | 0.33 | 0.27 | 2.96 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-14.70 Million | $-10.50 Million | $11.99 Million |
Windtree Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Windtree Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.61 |
| Latest Market Cap to Assets Ratio | 0.03 |
| Asset Growth Rate (YoY) | -14.0% |
| Total Assets | $27.88 Million |
| Market Capitalization | $793.77K USD |
Valuation Analysis
Below Book Valuation: The market values Windtree Therapeutics Inc's assets below their book value (0.03x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Windtree Therapeutics Inc's assets decreased by 14.0% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Windtree Therapeutics Inc (1995–2024)
The table below shows the annual total assets of Windtree Therapeutics Inc from 1995 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $27.88 Million | -13.98% |
| 2023-12-31 | $32.41 Million | -14.62% |
| 2022-12-31 | $37.95 Million | -49.25% |
| 2021-12-31 | $74.79 Million | -33.75% |
| 2020-12-31 | $112.89 Million | -5.12% |
| 2019-12-31 | $118.97 Million | -0.35% |
| 2018-12-31 | $119.40 Million | +3467.31% |
| 2017-12-31 | $3.35 Million | -65.49% |
| 2016-12-31 | $9.70 Million | -78.14% |
| 2015-12-31 | $44.38 Million | -6.57% |
| 2014-12-31 | $47.50 Million | -46.82% |
| 2013-12-31 | $89.32 Million | +198.29% |
| 2012-12-31 | $29.94 Million | +124.73% |
| 2011-12-31 | $13.32 Million | -8.34% |
| 2010-12-31 | $14.54 Million | -32.08% |
| 2009-12-31 | $21.40 Million | -34.92% |
| 2008-12-31 | $32.89 Million | -47.58% |
| 2007-12-31 | $62.74 Million | +82.40% |
| 2006-12-31 | $34.40 Million | -38.58% |
| 2005-12-31 | $56.01 Million | +48.81% |
| 2004-12-31 | $37.64 Million | +15.05% |
| 2003-12-31 | $32.72 Million | +55.33% |
| 2002-12-31 | $21.06 Million | +4.97% |
| 2001-12-31 | $20.07 Million | +1.76% |
| 2000-12-31 | $19.72 Million | +325.67% |
| 1999-12-31 | $4.63 Million | +0.70% |
| 1998-12-31 | $4.60 Million | -60.68% |
| 1997-12-31 | $11.70 Million | +515.79% |
| 1996-12-31 | $1.90 Million | -52.50% |
| 1995-12-31 | $4.00 Million | -- |
About Windtree Therapeutics Inc
Windtree Therapeutics, Inc., a biotechnology company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. Its lead product candidate is istaroxime, which is in Phase 2b clinical trials for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock. The company also develops AEROSURF, an aerosolized KL4 sur… Read more